NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger
NeOnc Technologies Holdings announced positive topline results from its NEO100-01 Phase 2a study showing 48.9% six-month progression-free survival and median overall survival of 26.09 months in patients with recurrent or progressive Grade III and IV IDH1-mutant glioma. The company plans to seek a Type B meeting with the FDA to discuss a potential r…